According to a recent LinkedIn post from Promise Bio, the company is emphasizing the importance of measuring proteoforms and post-translational modifications to better capture functional biological changes. The post uses JAK1, a well-studied inflammation regulator with established inhibitor drugs, to illustrate how traditional protein abundance metrics may miss clinically relevant effects.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that in inflammatory tissue, total JAK1 levels can appear unchanged even when treatments work, while specific proteoforms show clear modulation. This framing positions Promise Bio’s focus on more granular proteomics as a way to generate data that aligns more closely with actual cellular function.
The post suggests that such high-resolution functional readouts could be particularly valuable in less-characterized diseases and emerging therapies, where key biomarkers are not yet known. For investors, this points to a potential platform opportunity in advanced proteomics and “functional biology” that may support drug discovery, translational research, or companion diagnostic applications.
If Promise Bio can systematically apply proteoform and PTM analysis across complex disease areas, it could strengthen its competitive position in the growing proteomics and systems biology markets. This approach may attract interest from biopharma partners seeking more predictive biomarkers and could create monetization avenues through research collaborations, data products, or specialized analytical services.